Physician profile
Martin H Beerman
NPI 1902893639
$2,860.30
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,842 · 2020: $550 · 2021: $469.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.62 | 2019-2021 | |
| Gilead Sciences, INC. | $540.27 | 2019-2021 | |
| Pfizer INC. | $372.64 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.75 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $178.33 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.70 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $107.54 | 2019-2020 | |
| Janssen Biotech, INC. | $106.82 | 2019-2020 | |
| Ucb, INC. | $50.51 | 2019 | |
| Ferring Pharmaceuticals INC. | $44.47 | 2020 | |
| Shionogi INC | $24.14 | 2019 | |
| Allergan, INC. | $23.70 | 2020 | |
| Daiichi Sankyo INC. | $20.75 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.70 | 2021 | |
| Vivus LLC | $12.36 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Beerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.